MR-Linac-Guided Radiotherapy for Recurrent Prostate Cancer
This study, called TUMORNATOR II, is looking at a new way to treat prostate cancer that has come back after previous radiation therapy. It uses MR-Linac-guided Stereotactic Body Radiation Therapy (SBRT), a precise type of radiation, along with Androgen Deprivation Therapy (ADT) using medications like Leuprolide, Degarelix, or Relugolix. The main goal is to see how safe this treatment is and to track any urinary side effects over two years. You might be able to join if you are a man aged 18 or older with prostate cancer that has returned after prior external beam radiation therapy. The study plans to enroll 28 participants, but its current status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 28 participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for late toxicity (side effects) for at least 24 months (2 years) after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael Zelefsky, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Late toxicity (after 90 days) radiation-associated genitourinary (GU) and gastrointestinal (GI) eventsMonth 24
A serious toxicity event will be defined as any Grade 3 or higher genitourinary or gastrointestinal toxicity, based on NCI CTCAE v5.0.